FDA Provides Positive Feedback, Clears Path for Atossa to File IND for (Z)-Endoxifen in Metastatic Breast Cancer; FDA Indicates No Additional Toxicity Studies Required Exhibit 99.1 Atossa Therapeutics Announces Second Quarter 2025 Financial Results and Provides a Corporate Update Strong I-SPY2 Results Reinforce Ef icacy of Atossa's Monotherapy at 3-weeks SEATTLE, August 12, 2025 — Atossa Therapeutics, Inc. (Nasdaq: ATOS) (Atossa or the Company), a clinical-stage biopharmaceutical company developing innovati ...